United States Patent 10,952,986: Scope, claim map, and US gamma-hydroxybutyrate (GHB) sodium oxybate regimen patent landscape
Executive summary: US 10,952,986 is a US method patent directed to (i) a single daily-dose gamma-hydroxybutyrate (GHB) regimen equivalent to 3.0 to 12.0 g sodium oxybate, (ii) administered by opening a sachet, mixing with water, and orally dosing as a suspension, and (iii) multiple narcolepsy Type 1/Type 2 and symptom end-use statements, including bedtime, ~2 hours post-meal, and 6 to 8 hours of sleep. Dependent claims add dosing granularity (4.5/6.0/7.5/9.0 g equivalence) and formulation timing/PK “bioequivalent” constraints tied to specific figures. The claim scope is strongest against US products that replicate the sachet-mix-suspension workflow and the single-dose evening regimen. It is weaker against products that are (a) tablets/capsules, (b) ready-to-use liquids, (c) not sachet-based, (d) administered in split doses, or (e) not positioned at the specific post-prandial timing/PK relationships recited.
Important practical point: Because the independent claims recite a specific administration process (opening a sachet, mixing with water, orally administering the mixture), infringement risk concentrates on commercial products that use sachets and require water mixing shortly before ingestion, rather than merely delivering the same GHB dose.
How broad are the claims in US Patent 10,952,986 for gamma-hydroxybutyrate sachet mixing and single daily dosing?
Core answer: The patent’s breadth is defined by (1) dose equivalence, (2) single daily-dose timing, and (3) a sachet-to-water mixing administration method. The broadest independent claim (claim 1) covers a method for any disorder “treatable with gamma-hydroxybutyrate in a human” if the regimen matches the administration mechanics and dosing range.
Claim 1 scope elements (infringement-critical)
Claim 1 requires all of the following:
- A method of treating a disorder treatable with GHB in a human.
- Single daily dose (not split across time).
- Dose is GHB equivalent to 3.0 to 12.0 g sodium oxybate.
- Administration includes:
- opening a sachet containing a GHB formulation;
- mixing with water; and
- orally administering the mixture.
Implication: A competitor product that delivers GHB via:
- tablets/capsules,
- ready-to-drink liquids,
- pre-mixed suspensions in a final container,
- or administration not dependent on “opening a sachet” and mixing with water,
faces a direct claim construction barrier because claim 1 explicitly requires the sachet workflow.
Dependent claims tighten timing and user-experience outcomes
- Claim 2: dosing at bedtime.
- Claim 3: mixing shortly before oral administration.
- Claim 4: dosing approximately 2 hours after a meal.
- Claim 5: results in inducing sleep for 6 to 8 hours.
- Claim 6: dose equivalence specifically 4.5/6.0/7.5/9.0 g sodium oxybate.
Dependent claims tighten formulation state and mixing method
- Claim 7: mixture is a suspension.
- Claim 8: mixing includes pouring from sachet into a water-containing container.
- Claim 9: container initially has 50 mL of water (example-specific constraint).
Dependent claims 13–22 and 23–31 replicate the structure for narcolepsy and symptom outcomes
Claims 13–21 are narcolepsy Type 1/Type 2 methods with the same sachet-mix-suspension and dose range structure.
Claims 23–31 are symptom-reduction methods (excessive daytime sleepiness and cataplectic attacks) with the same sachet-mix-suspension and dose range structure.
What patents protect single daily-dose sodium oxybate versus split-dose regimens in US 10,952,986?
Key distinction in the claims: Claim 22 uses an explicit comparison limitation versus a split-dose immediate release liquid sodium oxybate regimen (half at t0 and half at t4h), and recites symptom/exposure reductions.
Claim 22: comparative “less confusion/less depressive syndrome” regimen limitation
Claim 22 requires:
- narcolepsy Type 1/Type 2 treatment,
- single daily dose range 3.0 to 12.0 g sodium oxybate equivalent,
- sachet-opening, mixing with water, and oral suspension administration (by incorporation from the base method structure),
- and a comparative performance statement:
- compared to split-dose regimen (half at t0, half at t4h of immediate release liquid sodium oxybate),
- the method produces less:
- confusion,
- depressive syndrome,
- incontinence,
- nausea,
- sleepwalking.
Implication for design-around: If an applicant or generic attempts to use a different dosing architecture that mirrors split dosing rather than a single daily dose, claim 22’s comparative limitation becomes difficult to satisfy. But the independent claim 1 still remains as a separate infringement pathway (because claim 1 does not require symptom reduction).
How do claims 10–12 lock scope to pharmacokinetic curves and “immediate release + modified release” portions?
Claims 10–12 add a second, more technical constraint: the method relies on a modified release formulation with immediate release and modified release portions and recites dose-specific and figure-specific PK bioequivalence.
Claim 10: dose + PK figure requirement (FIG. 11)
Claim 10 requires:
- treating a GHB-treatable disorder,
- administering a single dose,
- 4.5 g GHB,
- that yields a PK profile “as shown in FIG. 11,”
- with the dose comprising immediate release and modified release portions.
Scope effect: Infringement is contingent not only on the administration mechanics, but also on the formulation’s release architecture and PK match to the cited figure.
Claims 11–12: dose + timing post-meal + PK bioequivalence (FIG. 12 / FIG. 13)
Both claims require:
- a modified release formulation with immediate + modified release portions,
- doses of 4.5/6.0/7.5 g,
- given approximately two hours after a standardized evening meal,
- and yielding plasma concentration-time curves bioequivalent to those in FIG. 12 (claim 11) or FIG. 13 (claim 12).
Scope effect: These claims are more difficult to clear for competitors because:
- they require the timing relative to a meal,
- and a bioequivalence-to-figure PK standard.
For generic and follow-on formulation developers, these are the claims most likely to be attacked during prosecution or post-grant via written description/enablement, depending on how the patent discloses the formulation and the definition of bioequivalence to figure-based curves.
Does US 10,952,986 cover narcolepsy-specific indications and symptom reduction?
Yes. The patent includes multiple narcolepsy-focused method claims, including Type 1/Type 2 and excessive daytime sleepiness/cataplectic attack reduction.
Narcolepsy Type 1/Type 2 method claims
- Claims 13–21: narcolepsy Type 1/Type 2 treatment using the single daily dose sachet-mixing suspension protocol, with bedtime, ~2 hours post-meal, sleep duration, and dose equivalences.
- Claim 22: adds comparative symptom reduction versus split dosing.
Symptom reduction claims
- Claims 23–31: narcolepsy-related symptoms:
- excessive daytime sleepiness reduction
- reduced cataplectic attack frequency
- using the same single daily dose sachet-mixing suspension with timing/dose constraints in dependent claims.
Implication for enforcement: The narcolepsy claims can map to real-world prescribing and administration instructions. For litigation, the comparative claim 22 creates an additional evidentiary track: side effect and tolerability endpoints versus a split-dose comparator.
What formulation and administration workflow elements are required to infringe?
Claim 1’s administration workflow is the anchor. The following are infringement-critical for claim 1 and, by structure, for claims that depend on it:
- Sachet format: the formulation must be contained in a sachet at dispensing.
- Water mixing: the sachet contents are mixed with water.
- Oral administration of the mixture: the mixture is administered orally after mixing.
- Suspension state: for claim 7, the mixture is specifically a suspension.
- Timing of mixing: for claim 3, mixing occurs shortly before administration.
- Timing of administration: for claim 4, approximately 2 hours after a meal; claim 2 is bedtime.
- Dose equivalence range: 3.0 to 12.0 g sodium oxybate equivalent; dependent claims list specific equivalences.
- Container water volume (example) constraint: for claim 9, 50 mL water.
Design-around pathways most relevant to infringement risk:
- Replace sachets with unit-dose tablets/capsules (avoid “opening a sachet”).
- Provide ready-to-use liquid suspension with no mixing step.
- Maintain dose but shift away from the recited meal timing or avoid the single daily dosing pattern.
- Use formulation that does not create a suspension at the point of administration (harder to engineer because many reconstituted products are suspensions).
Where does the patent landscape sit versus known US GHB sodium oxybate products?
Because your request is about the US patent 10,952,986 claim scope rather than a complete Orange Book extraction, litigation history, or date-specific expiration schedule, the key landscape points are structural:
Landscape buckets for sodium oxybate / GHB in the US
- Immediate release (IR) sodium oxybate liquid with split dosing (classic night-time regimen).
- Extended-release / modified-release sodium oxybate formulations designed to provide evening/night dosing profiles.
- GHB prodrug or alternative delivery formats (when applicable to narcolepsy indications).
- Newer “reconstituted” or sachet-based workflows intended to improve dosing convenience.
US 10,952,986 most directly targets Bucket 2 plus a specific sachet-mix administration workflow, and secondarily targets Bucket 1-like split regimens via the comparative language of claim 22.
What would a generic or reformulation need to avoid to reduce exposure under 10,952,986?
Avoiding the sachet-mix-suspension workflow
If the competing product does not require:
- opening a sachet,
- mixing with water,
- administering the resulting mixture,
then claim 1 is hard to satisfy as written.
Avoiding single daily dosing and meal timing overlap
- Claim 1 is limited to a single daily dose.
- Claims 2–4 and the narcolepsy claim set push administration to bedtime and ~2 hours after eating.
If a competitor’s label uses split dosing or different timing, fewer dependent claims are implicated and the evidentiary match for comparative endpoints (claim 22) becomes less likely.
Avoiding the PK-figure constraints for claims 10–12
If a competitor cannot match the cited PK curves/bioequivalence at the recited meal timing, claims 10–12 become narrower and harder to enforce.
How strong is the patent estate around single daily-dose GHB if 10,952,986 is method-only?
Based on claim content alone, the enforceability posture depends on:
- the availability of a product that matches the exact administration steps,
- and whether the relevant commercial regimen is single daily and evening/post-meal positioned.
A “method-only” patent can still be strong against:
- manufacturers who support the method via instructions for use,
- and prescribers/patients in situations where direct infringement theories are used.
But it typically creates more litigation friction than product composition claims because plaintiffs must prove the real-world method elements.
Key claim-to-design mapping table for infringement and design-around
| Patent element |
Claim(s) |
Infringement trigger |
Common design-around |
| Single daily dose |
1, 13, 23, 22 |
Regimen is once daily |
Switch to split dosing |
| Dose range equivalence (3.0–12.0 g sodium oxybate equivalent) |
1, 13, 23 |
Dose matches within range |
Use out-of-range dosing or different equivalence |
| Treating “disorder treatable with GHB” |
1, 10–12 |
Indication fits GHB-treatable disorders |
Different therapeutic target (if feasible) |
| Sachet opening + mix with water + oral mixture |
1, 13, 23 (by structure) |
Workflow matches exactly |
Use tablets/capsules or ready-to-use liquid |
| Suspension mixture |
7, 19, 29 |
The administered mixture is a suspension |
Change formulation state at administration |
| Mixing shortly before dosing |
3, 15, 25 |
Timing matches instructions |
Mix earlier or use pre-mixed product |
| Bedtime administration |
2, 14, 24 |
Timing matches |
Change dosing time |
| ~2 hours after meal |
4, 16, 26 |
Timing matches post-prandial interval |
Change meal timing window |
| Induce 6–8 hours sleep |
5, 17, 27 |
Sleep duration observed |
Not applicable (hard to control) |
| Dose equivalence specifics (4.5/6.0/7.5/9.0 g) |
6, 18, 28 |
Specific doses used |
Use different doses |
| Modified release with IR + modified release portions |
10–12 |
Formulation release architecture matches |
Use all-IR or different architecture |
| PK profile/bioequivalent to figure curves |
10–12 |
PK timing match |
Reformulate away from PK curve |
When does US 10,952,986 lose exclusivity?
You did not provide:
- the application filing date,
- priority claims,
- prosecution history,
- or adjustment data.
Without those inputs, an exclusivity/expiration determination would require authoritative record retrieval beyond the claim text you supplied. No complete exclusivity timeline can be produced from the claims alone.
Which companies are likely at risk for licensing or Paragraph IV challenges on US 10,952,986?
Without Orange Book listings, ANDA/BLA status, or party names tied to the specific GHB product(s) matching the sachet-mix regimen, no accurate company-by-company litigation or challenge map can be generated from the claim text alone.
How does US 10,952,986 compare with split-dose sodium oxybate regimens in the claims?
The primary comparison appears in claim 22:
- Comparator: immediate release liquid sodium oxybate split dosing:
- Claimed benefit: “less” confusion, depressive syndrome, incontinence, nausea, sleepwalking.
This means claim 22 is positioned as a tolerability advantage for single daily dosing in narcolepsy relative to the established split-dose IR liquid approach. Claims 1/13/23 still cover the method even without the comparative tolerability outcomes, so the comparative clause mainly narrows claim 22 rather than eliminating infringement potential for the independent claim set.
Key Takeaways
- US 10,952,986 is method-centric and tightly tied to a sachet-opening + water-mixing + oral suspension administration workflow for a single daily dose of GHB equivalent to 3.0–12.0 g sodium oxybate.
- Narcolepsy Type 1/Type 2 coverage is explicit, with symptom reduction and a comparative tolerability claim (claim 22) versus split-dose IR liquid sodium oxybate.
- Claims 10–12 add formulation and PK constraints, requiring immediate release + modified release portions and figure/bioequivalence-linked plasma concentration-time profiles at ~2 hours post-meal.
- The most direct infringement path is a commercial product that reproduces the sachet workflow and single evening dosing structure; the most direct design-around is to eliminate the sachet-mix step or change dosing architecture away from the single daily evening regimen.
FAQs
1) Does US 10,952,986 require a specific GHB salt form or is “gamma-hydroxybutyrate” sufficient?
The claims use “gamma-hydroxybutyrate formulation” language and dose equivalence to sodium oxybate. On the face of the claim set you provided, the required identity is gamma-hydroxybutyrate, expressed as an equivalence to sodium oxybate.
2) Are bedtime and the “~2 hours after a meal” constraint required for claim 1 infringement?
No. Those elements are in dependent claims (2 and 4). Claim 1 itself requires the single daily dose, the dose equivalence range, and the sachet-mix-suspension administration steps.
3) Can a product that is single daily but not taken from a sachet avoid infringement of claim 1?
Yes, based on claim 1’s explicit requirement to open a sachet containing the formulation and mix with water.
4) Do claims 10–12 cover all GHB modified-release products?
Not as written. Claims 10–12 require the immediate release + modified release portions and a PK profile/bioequivalence linked to specific figures at specified doses and post-meal timing.
5) Does the comparative regimen in claim 22 matter for infringement of claims 1 or 13 or 23?
No. The comparative “less confusion/less depressive syndrome…” limitation is only in claim 22. Claims 1, 13, and 23 do not include that comparator language.
References (APA)
- US Patent 10,952,986. United States Patent and Trademark Office. (Claim text provided in prompt).
